Folate Receptor, Trop 2, Ovarian Cancer, and Antibody-Drug Conjugate (ADC)

Folate Receptor, Trop 2, Ovarian Cancer, and Antibody-Drug Conjugate (ADC)

Saved in:

Bibliographic Details
Main Authors:	Chinmoy K. Bose, Nirban Basu
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2025-08-01
Series:	Indian Journal of Medical and Paediatric Oncology
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0045-1806871
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age
by: Yi Liu, et al.
Published: (2025-12-01)

High Trop-2 expression in pulmonary sarcomatoid carcinoma reveals antibody–drug conjugate targeting Trop-2 is a promising therapeutic approach
by: Xiaoying Qian, et al.
Published: (2025-07-01)

Current progress and remaining challenges of peptide–drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)?
by: Dongyuan Wang, et al.
Published: (2025-04-01)

A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer
by: Brian C. Avanzino, et al.
Published: (2022-12-01)

Antibody drug conjugates
by: Stalin Bala, et al.
Published: (2020-01-01)

Synthesis, Radiolabeling, and Biological Evaluation of 68Ga-Mucin1 and Its Folate Hybrid Peptide Conjugates for the Diagnosis of Ovarian Cancer
by: Samiah Alhabardi, et al.
Published: (2021-01-01)

Advancements in antibody-drug conjugates as cancer therapeutics
by: Jung Yin Fong, et al.
Published: (2025-08-01)

Antibody-drug conjugates in breast cancer: advances and prospects
by: Zhiqiang Shi, et al.
Published: (2025-02-01)

Preparation of Trop2-targeted chimeric antigen receptor T cells and study of their exhaustion status in vitro
by: LIU Xiuying, et al.
Published: (2025-08-01)

Antibody-Drug Conjugates in Solid Tumors
by: Ilaria Colombo, et al.
Published: (2022-03-01)

Resistance to antibody–drug conjugates: A review
by: Sijia Li, et al.
Published: (2025-02-01)

The antibody–drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models
by: Dongli Liu, et al.
Published: (2025-04-01)

Une affaire trop sérieuse ?
by: Seppo Hentilä
Published: (2002-07-01)

Novel treatment approaches utilizing antibody-drug conjugates in breast cancer
by: Andrew A. Davis, et al.
Published: (2025-05-01)

Therapeutic index improvement of antibody-drug conjugates
by: Hans-Peter Gerber, et al.
Published: (2023-12-01)

Exploration of the antibody–drug conjugate clinical landscape
by: Heather Maecker, et al.
Published: (2023-12-01)

Improving the Cellular Accumulation of Folate-Conjugated Fully Chemically Modified siRNAs via 3′ Terminal Conjugation
by: Keiichi Motosawa, et al.
Published: (2025-07-01)

The Impact of Conjugation Mode and Site on Tubulysin Antibody‐Drug‐Conjugate Efficacy and Stability
by: Sayumi Yamazoe, et al.
Published: (2025-08-01)

In silico decrypting of the bystander effect in antibody–drug conjugates for breast cancer therapy
by: Víctor L. Cruz, et al.
Published: (2025-08-01)

Unlocking the Potential of Antibody-Drug Conjugates in Cancer Medicine: Efficacy and Side Effects
by: Marcus Vetter
Published: (2023-10-01)

Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations
by: Jiang Liu, et al.
Published: (2025-05-01)

Editorial: Antibody-drug conjugates in solid and hematologic malignancies
by: Khalil Saleh, et al.
Published: (2025-08-01)

AI-driven innovation in antibody-drug conjugate design
by: Heather A. Noriega, et al.
Published: (2025-06-01)

Expanding the potential of antibody–drug conjugates in gastrointestinal malignancies: beyond HER2 targets
by: P. Ntellas, et al.
Published: (2025-06-01)

Interrogating heterogeneity of cysteine-engineered antibody-drug conjugates and antibody-oligonucleotide conjugates by capillary zone electrophoresis-mass spectrometry
by: Tian Xu, et al.
Published: (2023-12-01)

The tricky effects of TROP2 in lung cancer: from clinical practice back to fundamental investigations
by: Renwang Liu, et al.
Published: (2025-08-01)

Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions
by: Fei Zhang, et al.
Published: (2025-05-01)

Unlocking the potential of antibody-drug conjugates in cervical cancer: emerging targets and clinical trials
by: Yue Zhang, et al.
Published: (2025-07-01)

Beyond HER2-Positive: The ADC Revolution in Breast Cancer Care
by: Marucs Vetter
Published: (2025-06-01)

Evaluation of thymidine kinase 1 and folate receptor alpha as potential biomarkers in prostate cancer
by: Sarah Ibrahim Ahmed, et al.
Published: (2025-08-01)

Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates
by: Tanu Dixit, et al.
Published: (2025-08-01)

Case Report: Unlocking opportunities in HER2-targeted antibody-drug conjugates for bulky leptomeningeal metastatic breast cancer
by: Alessandro Leal, et al.
Published: (2025-08-01)

Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48
by: Xin Gao, et al.
Published: (2025-08-01)

Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions
by: Pooja Patel, et al.
Published: (2025-07-01)

Troisième mandat présidentiel : le mandat de trop ?
by: Chérif Bennadji
Published: (2010-12-01)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-04-01)

Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer
by: Xiaojie Chu, et al.
Published: (2024-12-01)

Another power of antibody-drug conjugates: immunomodulatory effect and clinical applications
by: Ruotong Shi, et al.
Published: (2025-08-01)

Treatment-related adverse events of antibody drug-conjugates in clinical trials
by: Harold Nathan Tan, et al.
Published: (2025-07-01)

Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies
by: Yuying Jiang, et al.
Published: (2025-02-01)